Evercore ISI started coverage on shares of Iqvia (NYSE:IQV) in a research report report published on Thursday morning, MarketBeat Ratings reports. The firm issued an outperform rating and a $112.00 price objective on the medical research company’s stock.

Several other research analysts have also recently issued reports on the stock. Zacks Investment Research upgraded shares of Iqvia from a hold rating to a buy rating and set a $112.00 target price for the company in a report on Thursday. Mitsubishi UFJ Financial Group assumed coverage on shares of Iqvia in a report on Friday, December 15th. They issued a neutral rating and a $112.00 target price for the company. TheStreet upgraded shares of Iqvia from a c+ rating to a b rating in a report on Wednesday, December 13th. KeyCorp restated a sector weight rating and issued a $100.00 target price on shares of Iqvia in a report on Friday, November 10th. Finally, Morgan Stanley upped their target price on shares of Iqvia from $96.00 to $121.00 and gave the company an overweight rating in a report on Thursday, November 9th. Eight research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus price target of $107.79.

Iqvia (NYSE:IQV) opened at $103.00 on Thursday. Iqvia has a twelve month low of $74.80 and a twelve month high of $110.67. The company has a debt-to-equity ratio of 1.29, a current ratio of 1.22 and a quick ratio of 1.22. The stock has a market cap of $21,420.00, a price-to-earnings ratio of 355.17, a PEG ratio of 1.42 and a beta of 0.61.

Iqvia (NYSE:IQV) last issued its earnings results on Thursday, October 26th. The medical research company reported $1.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.14 by $0.05. Iqvia had a net margin of 0.58% and a return on equity of 12.60%. The business had revenue of $2.02 billion during the quarter, compared to analysts’ expectations of $2.01 billion. During the same quarter in the prior year, the business posted $1.00 EPS. The company’s revenue for the quarter was up 77.6% on a year-over-year basis. sell-side analysts expect that Iqvia will post 4.62 earnings per share for the current year.

In other news, insider Ari Bousbib sold 46,080 shares of the firm’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $108.14, for a total value of $4,983,091.20. Following the completion of the sale, the insider now owns 1,036,839 shares in the company, valued at approximately $112,123,769.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Cpp Investment Board Private H sold 7,497,807 shares of the firm’s stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $102.00, for a total transaction of $764,776,314.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 8,806,558 shares of company stock valued at $898,716,708. 6.40% of the stock is owned by company insiders.

Several hedge funds have recently added to or reduced their stakes in the company. Winslow Evans & Crocker Inc. acquired a new stake in shares of Iqvia in the 4th quarter worth $123,000. Livforsakringsbolaget Skandia Omsesidigt acquired a new stake in shares of Iqvia in the 4th quarter worth $209,000. Atria Investments LLC acquired a new stake in shares of Iqvia in the 4th quarter worth $218,000. Fox Run Management L.L.C. acquired a new stake in shares of Iqvia in the 4th quarter worth $250,000. Finally, Creative Planning acquired a new stake in shares of Iqvia in the 4th quarter worth $450,000. Institutional investors own 95.84% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Iqvia (IQV) Coverage Initiated at Evercore ISI” was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://theolympiareport.com/2018/01/22/iqvia-iqv-coverage-initiated-at-evercore-isi.html.

About Iqvia

IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.

Analyst Recommendations for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.